Levi & Korsinsky Launches Fraud Investigation on Behalf of ADMA Biologics, Inc. (ADMA) Shareholders
New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ: ADMA) concerning potential violations of the federal securities laws. On the Q4 2025 earnings call, CEO Adam Grossman stated "ASCENIV achieved $363 million in net revenue, representing 51% year-over-year growth." Culper Research's short report contends ASCENIV only achieved its growth on the back of...
2026-03-30 12:10 AM EDT
ATTENTION Insulet Corporation (PODD) Investors: Possible Fraud - Contact Levi & Korsinsky Today
New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Insulet Corporation ("Insulet Corporation") (NASDAQ: PODD) concerning potential violations of the federal securities laws. During that same February 18 earnings call, McEvoy stated that "strong clinical evidence and real-world outcomes continue to earn prescriber and patient confidence" and described Omnipod 5 as the "favorite pump" for both type-1 and type-2...
2026-03-30 12:08 AM EDT
GOSS ALERT: Ongoing Investigation Into Gossamer Bio, Inc. - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. ("Gossamer Bio, Inc.") (NASDAQ: GOSS) concerning potential violations of the federal securities laws. Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Company's pivotal Phase 3 trial evaluating the drug in pulmonary arterial hypertension. The Company had publicly characterized the PROSERA patient...
2026-03-30 12:06 AM EDT
Fraud Investigation: Levi & Korsinsky Investigates Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Shareholders
New York, New York--(Newsfile Corp. - March 27, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ: ALDX) concerning potential violations of the federal securities laws. Throughout 2024 and 2025, Aldeyra's made forward-looking statements regarding the development and regulatory prospects of reproxalap for the treatment of dry eye disease. Management described the NDA submission and review...
2026-03-27 3:38 PM EDT
Did You Suffer Losses in ADMA Biologics, Inc. (ADMA)? Contact Levi & Korsinsky About Securities Fraud Claims
New York, New York--(Newsfile Corp. - March 27, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ: ADMA) concerning potential violations of the federal securities laws. On the Q4 2025 earnings call, CEO Adam Grossman stated "ASCENIV achieved $363 million in net revenue, representing 51% year-over-year growth." Culper Research's short report contends ASCENIV only achieved its growth on the back of...
2026-03-27 11:50 AM EDT
Fraud Investigation Opened: Levi & Korsinsky Investigates Freshpet, Inc. (FRPT) on Behalf of Shareholders
New York, New York--(Newsfile Corp. - March 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Freshpet, Inc. ("Freshpet, Inc.") (NASDAQ: FRPT) concerning potential violations of the federal securities laws. On March 17, 2026, an NAD ruling came through after a Fast-Track SWIFT challenge, an expedited single-issue process, was brought by one of Freshpet's competitors, The Farmer's Dog. The Farmer's Dog argued that three of Freshpet's video ads included...
2026-03-25 9:47 AM EDT
Shareholders Alert: Investigation Into Gossamer Bio, Inc. (GOSS) - Contact Levi & Korsinsky to Protect Your Rights
New York, New York--(Newsfile Corp. - March 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer Bio, Inc.") concerning potential violations of the federal securities laws. Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Company's pivotal Phase 3 trial evaluating the drug in pulmonary arterial hypertension. The Company had publicly characterized the PROSERA patient...
2026-03-23 12:15 AM EDT
Securities Investigation: Levi & Korsinsky Investigates Disc Medicine, Inc. (IRON) on Behalf of Investors
New York, New York--(Newsfile Corp. - March 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. (NASDAQ: IRON) ("Disc Medicine, Inc.") concerning potential violations of the federal securities laws. On February 13, 2026, Disc disclosed that the FDA had issued a Complete Response Letter (CRL) for bitopertin, the company's lead therapeutic candidate targeting EPP, a rare genetic disorder characterized by extreme photosensitivity. A CRL...
2026-03-23 12:13 AM EDT
Fraud Investigation: Levi & Korsinsky Investigates Immutep Limited (IMMP) on Behalf of Shareholders
New York, New York--(Newsfile Corp. - March 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Immutep Limited (NASDAQ: IMMP) ("Immutep Limited") concerning potential violations of the federal securities laws. On January 30, 2026, Immutep filed a 6-K with the SEC stating that the TACTI-004 futility analysis was "on track for the first quarter of CY2026" and cited "strong operational progress" for the trial. The filing contained no reference to negative...
2026-03-23 12:11 AM EDT
PODD ACTIVE INVESTIGATION: Lost Money on Insulet Corporation? Contact Levi & Korsinsky Now
New York, New York--(Newsfile Corp. - March 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Insulet Corporation (NASDAQ: PODD) ("Insulet Corporation") concerning potential violations of the federal securities laws. During that same February 18 earnings call, McEvoy stated that "strong clinical evidence and real-world outcomes continue to earn prescriber and patient confidence" and described Omnipod 5 as the "favorite pump" for both type-1 and type-2...
2026-03-23 12:08 AM EDT
Potential Securities Fraud: Levi & Korsinsky Investigates Aldeyra Therapeutics, Inc. (ALDX)
New York, New York--(Newsfile Corp. - March 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ: ALDX) concerning potential violations of the federal securities laws. Throughout 2024 and 2025, Aldeyra's made forward-looking statements regarding the development and regulatory prospects of reproxalap for the treatment of dry eye disease. Management described the NDA submission and review...
2026-03-18 12:34 PM EDT
Disc Medicine, Inc. (IRON) Under Investigation for Potential Securities Law Violations - Contact Levi & Korsinsky Today
New York, New York--(Newsfile Corp. - March 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. ("Disc Medicine, Inc.") (NASDAQ: IRON) concerning potential violations of the federal securities laws. On February 13, 2026, Disc disclosed that the FDA had issued a Complete Response Letter (CRL) for bitopertin, the company's lead therapeutic candidate targeting EPP, a rare genetic disorder characterized by extreme photosensitivity. A CRL...
2026-03-18 10:41 AM EDT
Ongoing Investigation into Immutep Limited (IMMP): Contact Levi & Korsinsky About Potential Fraud
New York, New York--(Newsfile Corp. - March 17, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Immutep Limited ("Immutep Limited") (NASDAQ: IMMP) concerning potential violations of the federal securities laws. On January 30, 2026, Immutep filed a 6-K with the SEC stating that the TACTI-004 futility analysis was "on track for the first quarter of CY2026" and cited "strong operational progress" for the trial. The filing contained no reference to negative...
2026-03-17 11:46 AM EDT
ATTENTION Insulet Corporation (PODD) Investors: Possible Fraud - Contact Levi & Korsinsky Today
New York, New York--(Newsfile Corp. - March 17, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Insulet Corporation ("Insulet Corporation") (NASDAQ: PODD) concerning potential violations of the federal securities laws. During that same February 18 earnings call, McEvoy stated that "strong clinical evidence and real-world outcomes continue to earn prescriber and patient confidence" and described Omnipod 5 as the "favorite pump" for both type-1 and type-2...
2026-03-17 11:45 AM EDT
ALIT ALERT: Levi & Korsinsky Investigates Alight, Inc. on Behalf of Shareholders Who Lost Money
New York, New York--(Newsfile Corp. - March 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Alight, Inc. (NYSE: ALIT) ("Alight, Inc.") concerning potential violations of the federal securities laws. Alight's Q4 2025 results landed below the low end of the Company's own full-year 2025 guidance range. On the Q3 2025 earnings call on November 5, 2025, CFO Jeremy Heaton told investors the Company expected full-year 2025 EPS of $0.54 to $0.58 and revenue...
2026-03-16 12:29 AM EDT
Levi & Korsinsky Investigating Whether PROCEPT BioRobotics Corporation (PRCT) Misled Investors - Securities Law Violations Possible
New York, New York--(Newsfile Corp. - March 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into PROCEPT BioRobotics Corporation (NASDAQ: PRCT) ("PROCEPT BioRobotics Corporation") concerning potential violations of the federal securities laws. On the Q3 2025 earnings call on November 4, 2025, CFO Kevin Waters reaffirmed the $325.5 million revenue target and stated the company was "maintaining handpiece average selling prices to be approximately $3,200."...
2026-03-16 12:27 AM EDT
Lost Money on Gartner, Inc. (IT)? Contact Levi & Korsinsky to Protect Your Rights
New York, New York--(Newsfile Corp. - March 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gartner, Inc. (NYSE: IT) ("Gartner, Inc.") concerning potential violations of the federal securities laws. SEC Regulation G and Item 10(e) of Regulation S-K establish disclosure requirements for companies presenting non-GAAP financial measures. These rules require that adjusted metrics be reconciled to the most directly comparable GAAP measure and that GAAP...
2026-03-16 12:24 AM EDT
Ongoing Investigation: Grocery Outlet Holding Corp. (GO) May Have Misled Shareholders - Levi & Korsinsky Investigates
New York, New York--(Newsfile Corp. - March 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Grocery Outlet Holding Corp. (NASDAQ: GO) ("Grocery Outlet Holding Corp.") concerning potential violations of the federal securities laws. On the Q3 2025 earnings call on November 4, 2025, management narrowed the FY2025 comparable-store sales outlook to 0.6%-0.9%, down from 0.6%-1.2%. Management nevertheless reiterated confidence in the outlook for gross...
2026-03-16 12:21 AM EDT
ICLR ALERT: Ongoing Investigation Into ICON Public Limited Company - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - March 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ICON Public Limited Company (NASDAQ: ICLR) ("ICON Public Limited Company") concerning potential violations of the federal securities laws. The magnitude of the single-day decline wiped out billions of dollars of shareholder value and represented one of the largest percentage drops in the CRO sector in recent years. Prior to the disclosure, ICLR had traded in...
2026-03-16 12:17 AM EDT
Investigation Alert: Gossamer Bio, Inc. (GOSS) Under Scrutiny - Contact Levi & Korsinsky for Details
New York, New York--(Newsfile Corp. - March 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer Bio, Inc.") concerning potential violations of the federal securities laws. Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Company's pivotal Phase 3 trial evaluating the drug in pulmonary arterial hypertension. The Company had publicly characterized the PROSERA patient...
2026-03-16 12:12 AM EDT